Product image of Lackepila (Lacosamide) supplied by GNH India

Lackepila

Active Ingredient:
Lacosamide
Origin:
EU

Lackepila (Lacosamide)

Lacosamide, the active ingredient in Lackepila, is an anticonvulsant presented as an oral tablet for oral use. It belongs to the sodium‑channel blocker class and is employed to treat partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve quality of life.

GNH India supplies Lackepila as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Manufacturer / TM Owner

Farmak International Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide is an anticonvulsant indicated for seizure disorders within the epilepsy disease family.

  • Partial-onset seizures: reduces seizure frequency as adjunctive therapy in patients with focal epilepsy.
  • Focal epilepsy: provides additional seizure control when first‑line agents are insufficient.
  • Adjunctive therapy for refractory seizures: enhances overall seizure management in patients not fully controlled by other antiepileptics.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and thereby decreasing repetitive neuronal firing that underlies seizure activity.

Side Effects

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dizziness: transient sensation of light‑headedness.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional throbbing pain.
  • Fatigue: feeling unusually tired.
  • Blurred vision: temporary visual disturbances.
  • Diplopia: double vision in some patients.

Serious or Rare Side Effects

  • Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conduction disorders.
  • Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Suicidal ideation: emergence of thoughts of self‑harm.
  • Hypersensitivity: including rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: abnormal liver enzymes or liver injury.
  • Respiratory depression: slowed breathing in severe cases.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety factors.

  • Renal impairment: adjust dosage in patients with severe renal dysfunction.
  • Hepatic impairment: monitor liver function tests regularly.
  • Cardiac conduction disorders: avoid use in patients with known PR‑interval prolongation or other significant conduction abnormalities.
  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Driving and operating machinery: caution patients about dizziness or visual changes that may affect performance.
  • Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in the original packaging.

Avoid Interactions

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
  • Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide effectiveness.
  • Concurrent use with other sodium‑channel blockers: heightened risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely)

  • Alcohol: may exacerbate central nervous system depression.
  • Hormonal contraceptives: lacosamide may reduce contraceptive efficacy.
  • Other antiepileptic drugs: dose adjustments may be needed based on therapeutic response.
  • Antihypertensive agents: monitor blood pressure as additive effects are possible.
  • Antidepressants: watch for increased risk of mood changes.

Frequently Asked Questions

Lackepila contains the active ingredient lacosamide and is prescribed to treat partial‑onset seizures in patients with epilepsy. It is used as an adjunctive therapy to help reduce the frequency of focal seizures when other antiepileptic drugs alone are insufficient.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces the ability of neurons to fire repetitively, thereby decreasing the hyperexcitability that leads to seizure activity.

The appropriate dose of Lackepila is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any relevant renal or hepatic considerations. Dosage titration follows established medical guidelines and should not be self‑adjusted.

Safety data for lacosamide during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lackepila.

To request Lackepila, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lackepila (lacosamide) differs from traditional sodium‑channel blockers such as carbamazepine by selectively enhancing slow inactivation rather than fast inactivation. This mechanism may result in a distinct side‑effect profile and fewer drug‑interaction concerns, though individual response varies and therapy should be individualized by a neurologist.

Lackepila tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lackepila is taken orally as a tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their prescriber. Consistency in timing and adherence to the prescribed titration schedule are important for optimal seizure control.

Serious risks include cardiac arrhythmias, especially in patients with existing conduction abnormalities, severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behaviors, and significant hepatic dysfunction. Any new or worsening symptoms should be reported to a healthcare professional promptly.

Lackepila should be avoided in individuals with known hypersensitivity to lacosamide or any of its excipients, and in patients with significant cardiac conduction disorders (e.g., prolonged PR interval) unless closely monitored. It is also contraindicated in patients for whom the prescriber determines the risks outweigh the therapeutic benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT